FORM 10-Q

United States
                                                  Securities and Exchange Commission
                                                       Washington, D. C. 20549

(Mark One)

X                     Quarterly Report Pursuant to Section 13 or 15(d)
                                                                                               of the Securities Exchange Act of 1934

For Quarter Ended: February 28, 2003
OR

_                      Transition Report Pursuant to Section 13 or 15(d)
                                                                                                of the Securities Exchange Act of 1934

Commission File Number: 0-14820IMMUCOR, INC.
(Exact name of registrant as specified in its charter)

       Georgia                                      22-2408354
                  (State or other jurisdiction of                                 (I.R.S. Employer
                  incorporation or organization)                      Identification No.)

3130 Gateway Drive       P.O. Box 5625       Norcross, Georgia 30091-5625
                                        (Address of principal executive offices)          (Zip Code)

Registrant's telephone number: (770) 441-2051

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.

Yes X   No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes X   No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as
of the latest practicable date.

As of March 28, 2003: Common Stock, $0.10 Par Value - 12,759,015

---

|                                                                                 
|---------------------------------------------------------------------------------
|
|ASSETS                                                                           
|                                                                                 
|CURRENT ASSETS:                                                                  
|Cash and cash equivalents                                                        
|Accounts receivable, trade (less allowance for doubtful accounts of $1,938,144 at
|February 28, 2003 and $1,483,688 at May 31, 2002)                                
|Inventories                                                                      
|Income taxes receivable                                                          
|Deferred income taxes                                                            
|Prepaid expenses and other                                                       
|                                                                                 
|Total current assets                                                             
|                                                                                 
|LONG-TERM INVESTMENT - At cost                                                   
|                                                                                 
|PROPERTY, PLANT AND EQUIPMENT - Net                                              
|                                                                                 
|DEFERRED INCOME TAXES                                                            
|                                                                                 
|OTHER ASSETS - Net                                                               
|                                                                                 
|DEFERRED LICENSING COSTS - Net                                                   
|                                                                                 
|CUSTOMER LIST - Net                                                              
|                                                                                 
|EXCESS OF COST OVER NET TANGIBLE ASSETS ACQUIRED - Net                           
|                                                                                 
|                                                                                 
|                                                                                 

See notes to consolidated financial
statements.

---

|                                                                             
|-----------------------------------------------------------------------------
|
|LIABILITIES AND SHAREHOLDERS' EQUITY                                         
|                                                                             
|CURRENT LIABILITIES:                                                         
|Current portion of borrowings under bank line of credit agreements           
|Current portion of long-term debt                                            
|Current portion of capital lease obligations                                 
|Accounts payable                                                             
|Income taxes payable                                                         
|Accrued salaries and wages                                                   
|Deferred income taxes                                                        
|Other accrued liabilities                                                    
|                                                                             
|Total current liabilities                                                    
|                                                                             
|BORROWINGS UNDER BANK LINE OF CREDIT AGREEMENTS -    Net of current portion  
|                                                                             
|LONG-TERM DEBT - Net of current portion                                      
|                                                                             
|CAPITAL LEASE OBLIGATIONS - Net of current portion                           
|                                                                             
|DEFERRED INCOME TAXES                                                        
|                                                                             
|OTHER LIABILITIES                                                            
|                                                                             
|SHAREHOLDERS' EQUITY:                                                        
|Common stock -  authorized 45,000,000 shares, $0.10 par value; 12,753,089 and
|11,555,645 issued and outstanding at February 28, 2003 and May 31, 2002,     
|respectively                                                                 
|Additional paid-in capital                                                   
|Retained earnings                                                            
|Accumulated other comprehensive loss                                         
|                                                                             
|Total shareholders' equity                                                   
|                                                                             
|                                                                             
|                                                                             

See notes to consolidated financial statements.

---

|                                    
|------------------------------------
|
|
|
|
|                                    
|NET SALES                           
|                                    
|COST OF SALES                       
|                                    
|GROSS MARGIN                        
|                                    
|OPERATING EXPENSES:                 
|Research and development            
|Selling and marketing               
|Distribution                        
|General and administrative          
|Amortization expense                
|                                    
|Total operating expenses            
|                                    
|INCOME FROM OPERATIONS              
|                                    
|OTHER INCOME (EXPENSE):             
|Interest income                     
|Interest expense                    
|Other - net                         
|                                    
|Total other                         
|                                    
|INCOME BEFORE INCOME TAXES          
|INCOME TAX EXPENSE                  
|                                    
|NET INCOME                          
|                                    
|Earnings per share:                 
|Basic                               
|                                    
|Diluted                             
|                                    
|Weighted average shares outstanding:
|Basic                               
|                                    
|Diluted                             
|                                    

See notes to consolidated financial statements.

---

|                                                                                 
|---------------------------------------------------------------------------------
|
|
|
|                                                                                 
|OPERATING ACTIVITIES:                                                            
|Net income                                                                       
|Adjustments to reconcile net income to net cash provided by operating activities:
|Depreciation and amortization of property and equipment                          
|Amortization of other assets and excess of cost over net tangible assets acquired
|Amortization of debt issue costs                                                 
|Provision for doubtful accounts                                                  
|Disposal of assets in settlement                                                 
|Impairment of fixed assets                                                       
|Deferred tax provision                                                           
|Changes in operating assets and liabilities:                                     
|Accounts receivable, trade                                                       
|Loan to officer                                                                  
|Income taxes                                                                     
|Inventories                                                                      
|Other current assets                                                             
|Other long-term assets                                                           
|Accounts payable                                                                 
|Other current liabilities                                                        
|Other long-term liabilities                                                      
|                                                                                 
|Total adjustments                                                                
|                                                                                 
|Cash provided by operating activities                                            
|                                                                                 
|INVESTING ACTIVITIES:                                                            
|Purchases of / deposits on property and equipment                                
|                                                                                 
|Cash used in investing activities                                                
|                                                                                 
|FINANCING ACTIVITIES:                                                            
|Borrowings under line of credit agreements net of repayments                     
|Repayment of notes payable                                                       
|Payments of long-term debt and capital lease obligations net of borrowings       
|Payment of debt issue costs                                                      
|Exercise of stock options and warrants (1,044,892 shares and 6,500 shares,       
|respectively)                                                                    
|                                                                                 
|Cash used in financing activities                                                
|                                                                                 
|EFFECT OF EXCHANGE RATE CHANGES ON CASH                                          
|                                                                                 
|INCREASE IN CASH AND CASH EQUIVALENTS                                            
|CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                 
|                                                                                 
|CASH AND CASH EQUIVALENTS AT END OF PERIOD                                       
|                                                                                 

Significant Non-Cash
Activities:

The Italian subsidiary has entered
into various capital lease obligations to finance approximately $0.8 million of
instruments installed at customer sites under reagent agreements.

See notes to consolidated financial
statements.

---

IMMUCOR, INC.

Notes to Consolidated
Financial Statements

(Unaudited)

1. BASIS OF PRESENTATION

The accompanying unaudited
consolidated financial statements have been prepared in accordance with accounting
principles generally accepted in the United States for interim financial information and
the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not
include all of the information and footnotes required by accounting principles generally
accepted in the United States for complete financial statements. However, there has been
no material change in the information disclosed in the Companys annual financial
statements dated May 31, 2002, except as disclosed herein. In the opinion of management,
all adjustments (consisting of normal recurring accruals) considered necessary for a fair
presentation have been included. Operating results for the three-month and nine-month
periods ended February 28, 2003 are not necessarily indicative of the results that may be
expected for the year ending May 31, 2003. For further information, refer to the
consolidated financial statements and footnotes thereto included in the Companys
Annual Report on Form 10-K for the year ended May 31, 2002.

Certain prior year balances have been
reclassified to conform to the current year presentation.

2. INVENTORIES

Inventories are stated at the lower
of first-in, first-out cost or market:

|                           | As of
February 28, 2003 | As of
May 31, 2002 | 
|-------------------------- | ----------------------- | ------------------ | 
|Raw materials and supplies |                         | $ 6,855,906        | 
|Work in process            |                         | 1,803,306          | 
|Finished goods             |                         | 9,595,722          | 
|                           |                         |                    | 
|                           |                         | $18,254,934        | 
|                           |                         |                    | 

3. EARNINGS PER SHARE

The following table sets forth the
computation of basic and diluted earnings per share in accordance with Statement of
Financial Accounting Standards (SFAS) No. 128, Earnings per Share. The
Company implemented a three-for-two stock split on September 13, 2002 to shareholders of
record as of the close of business on August 26, 2002. The split was effected in the form
of a 50% stock dividend. All share and per share amounts disclosed in this document have
been restated to reflect this stock split discussed in Note 8 to the consolidated
financial statements.

|                                                    | Three Months Ended | Nine Months Ended
|--------------------------------------------------- | ------------------ | -----------------
|
|                                                    |                    |                  
|Numerator for basic and diluted earnings per share: |                    |                  
|Income available to common shareholders             |                    | $  3,748,829     
|                                                    |                    |                  
|Denominator:                                        |                   
|For basic earnings per share - weighted             |                   
|average shares basis                                |                    | 12,681,697       
|Effect of dilutive stock options and warrants       |                    | 900,120          
|                                                    |                    |                  
|Denominator for diluted earnings per share          |                   
|-adjusted weighted average shares basis             |                    | 13,581,817       
|                                                    |                    |                  
|Basic earnings per share                            |                    | $           0.30 
|                                                    |                    |                  
|Diluted earnings per share                          |                    | $           0.28 
|                                                    |                    |                  

---

4.  DOMESTIC AND FOREIGN OPERATIONS

Information concerning the Company's domestic and foreign operations is summarized below (in 000s):



|                             
|-----------------------------
|                             
|
|                             
|                             
|Net reagent revenues:        
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Net instrument revenues:     
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Income from operations       
|Net income (loss)            
|                             
|
|                             
|                             
|Net reagent revenues:        
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Net instrument revenues:     
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Income (loss) from operations
|Net income (loss)            
|                             
|
|                             
|                             
|Net reagent revenues:        
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Net instrument revenues:     
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Income from operations       
|Net income (loss)            
|                             
|
|                             
|                             
|Net reagent revenues:        
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Net instrument revenues:     
|Unaffiliated customers       
|Affiliates                   
|                             
|Total                        
|Income (loss) from operations
|Net income (loss)            

The Companys U.S. operations
made net export sales to unaffiliated customers of approximately $1,261,000 and $1,124,000
for the three months ended February 28, 2003 and 2002, respectively, and $3,498,000 and
$3,871,000 for the nine months ended February 28, 2003 and 2002, respectively. The
Companys German operations made net export sales to unaffiliated customers of
approximately$961,000 and $567,000 for the three months ended February 28, 2003
and 2002, respectively, and $2,520,000 and $1,582,000 for the nine months ended February
28, 2003 and 2002, respectively. The Companys Canadian operations made net export
sales to unaffiliated customers of approximately$533,000 and $598,000 for the
three months ended February 28, 2003 and 2002, respectively, and $1,643,000 and $1,500,000
for the nine months ended February 28, 2003 and 2002, respectively. Product sales to
affiliates are valued at market prices.

---

5.    
          COMPREHENSIVE INCOME

The components of comprehensive income for the three-month and nine-month periods ended February 28, 2003 and 2002 are as follows:

|                                          | Three Months Ended | Nine Months Ended
|----------------------------------------- | ------------------ | -----------------
|
|
|                                          |                    |                  
|Net income                                |                    | $3,748,829       
|Net foreign currency translation          |                    | 1,913,915        
|Net derivatives qualifying as hedges      |                    | --               
|Cumulative effect of the adoption of SFAS |                   
|133 on June 1, 2001, net of taxes         |                    | --               
|Hedge loss reclassified into earnings     |                    | 5,137            
|                                          |                    |                  
|Comprehensive income                      |                    | $5,667,881       
|                                          |                    |                  

Accumulated comprehensive loss as of February
28, 2003 and May 31, 2002 was ($2,952,598) and ($5,394,698), respectively. The balance,
consisting primarily of net losses on foreign currency translation adjustments, has been
disclosed in the shareholders equity section of the consolidated balance sheets.

6.    
          IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS

In June 1998, the Financial
Accounting Standards Board (FASB) issued SFAS No. 133, Accounting for
Derivative Instruments and Hedging Activities. This statement provides a comprehensive
and consistent standard for the recognition and measurement of derivatives and hedging
activities. In June 2000, the FASB issued SFAS No. 138, Accounting for Certain
Derivative Instruments and Certain Hedging Activities-an Amendment to FASB Statement No.
133. This statement amended certain provisions of SFAS No. 133. Accordingly, the
Company adopted SFAS No. 133, as amended by SFAS No. 138, effective the first quarter of
fiscal 2002. The cumulative effect of the adoption of SFAS No. 133 on June 1, 2001
resulted in a comprehensive loss (a component of Shareholders Equity on the balance
sheet) of approximately $103,000, net of $26,000 in income taxes, relating to the interest
rate swap agreements.  Due to the ineffectiveness of the swap related to the U.S. loan, approximately $5,100 and $15,400 was
reclassified from comprehensive loss to earnings as interest expense and approximately
$93,100  and $324,400 was charged directly to interest expense for the
three-month and nine-month periods ended February 28, 2003, respectively.

See Note 9 to the consolidated
financial statements for a discussion of SFAS No. 141, Business Combinations and
SFAS No. 142, Goodwill and Other Intangible Assets.

In June 2001, the FASB issued SFAS
No. 143, Accounting for Asset Retirement Obligations. Statement 143 applies to
legal obligations associated with the retirement of long-lived assets that result from the
acquisition, construction, development and/or the normal operation of a long-lived asset.
For the purposes of Statement 143, a legal obligation is an obligation that a party is
required to settle as a result of an existing or enacted law, statute, ordinance, or
written or oral contract or that are based on a promise and an expectation of performance.
Statement 143 is effective for financial statements for fiscal years beginning after June
15, 2002. The impact of adopting the Statement is recognized as a cumulative effect of a
change in accounting principle as of the beginning of a companys fiscal year in
which the Statement is first applied. The Company is in the process of evaluating the
impact SFAS No. 143 will have upon adoption but does not anticipate it will have a
significant impact on its financial position or results of operations.

In October 2001, the FASB issued SFAS
No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. The
Statement supercedes SFAS No. 121, Accounting for the Impairment of Long-Lived Assets
and for Long-Lived Assets to be Disposed of,however it retains the fundamental
provisions of that statement related to the recognition and measurement of the impairment
of long-lived assets to be held and used. The Statement is effective for
year-ends beginning after December 15, 2001. The Company adopted SFAS No. 144 effective
June 1, 2002 without impact on its financial position or results of operations.

In July 2002, the FASB issued SFAS
No. 146, Accounting for Costs Associated with Exit or Disposal Activities, which
addresses financial accounting and reporting for costs associated with exit or disposal
activities and nullifies Emerging Issues Task Force (EITF) Issue No. 94-3, Liability Recognition for
Certain Employee Termination Benefits and Other Costs to Exit an Activity (including
certain costs incurred in a restructuring). The provisions of SFAS No. 146 are
effective for exit or disposal activities that are initiated after December 31, 2002. The
Company does not expect that the adoption of SFAS No. 146 will have a material impact on
its financial statements.

In November 2002, the FASB issued
Interpretation No. 45, Guarantors Accounting and Disclosure Requirements for
Guarantees (FIN No. 45). FIN No. 45 requires a guarantor to recognize, at the
inception of a guarantee, a liability for the fair value of the obligation it has
undertaken in issuing the guarantee. The Company will apply FIN No. 45 to guarantees, if
any, issued or modified after December 31, 2002. At adoption, FIN No. 45 did not have a
significant impact on the Companys consolidated statements of operations or
financial position. FIN No. 45 also requires guarantors to disclose certain information
for guarantees, including product warranties, outstanding at the end of interim periods
ending after December 15, 2002. The Company does not have any material warranty
obligations or other guarantees as of February 28, 2003.

In November 2002, the EITF reached a
consensus on EITF Issue No. 00-21, Revenue Arrangements with Multiple Deliverables
(EITF 00-21). The Issue addresses certain aspects of the accounting for
arrangements under which a vendor will perform multiple revenue-generating activities.
EITF 00-21 addresses when a revenue arrangement with multiple deliverables should be
divided into separate units of accounting and, if separation is appropriate, how the
arrangement consideration should be allocated to the identified accounting units. The
Company is required to adopt the provisions of EITF 00-21 effective July 1, 2003, and the
Company does not expect the adoption of EITF 00-21 to have a material impact on its
financial statements.

In December 2002, the FASB issued
SFAS No. 148, Accounting for Stock-Based Compensation  Transition and Disclosure
 an amendment of FASB Statement No. 123.This Statement provides alternative
methods of transition for a voluntary change to the fair value based method of accounting
for stock-based employee compensation. In addition, this Statement amends the disclosure
requirements of Statement 123 to require prominent disclosures in both annual and interim
financial statements about the method of accounting for stock-based employee compensation
and the effect of the method used on reported results. The interim disclosure requirements
are effective for financial reports containing condensed consolidated financial statements
for interim periods beginning after December 15, 2002. Consequently, the Company will
adopt the interim disclosure requirements with the period ended May 31, 2003.

In January 2003, the FASB issued
Interpretation No. 46, Consolidation of Variable Interest Entities, an Interpretation
of Accounting Research Bulletin (ARB) No. 51 (FIN No. 46). FIN No. 46
requires certain variable interest entities, or VIEs, to be consolidated by the primary
beneficiary of the entity if the equity investors in the entity do not have the
characteristics of a controlling financial interest or do not have sufficient equity at
risk for the entity to finance its activities without additional subordinated financial
support from other parties. FIN No. 46 is effective for all VIEs created or acquired after
January 31, 2003. For VIEs created or acquired prior to February 1, 2003, the provisions
of FIN No. 46 must be applied for the first interim or annual period beginning after June
15, 2003. The Company does not expect that the adoption of FIN No. 46 will have a material
impact on its financial statements.

---

7.    
          INCOME TAXES

Income tax expense for the
three-month and nine-month periods ended February 28, 2003 of approximately $1,556,000 and
$5,282,000, respectively, was greater as a percentage of pre-tax income than income tax
expense of approximately $748,000 and $1,564,000 as a percentage of pre-tax income for the
three-month and nine-month periods ended February 28, 2002, respectively, primarily due to
net operating loss carry-forwards utilized during the prior year.

8.    
          STOCK SPLIT

On July 24, 2002, the Board of
Directors approved a three-for-two stock split, which was effected in the form of a 50%
stock dividend. The date of distribution was September 13, 2002 to the shareholders of
record at the close of business on August 26, 2002. The number of shares outstanding at
the close of business on August 26, 2002 was 8,257,277. The stock split added an
additional 4,128,639 shares to outstanding shares. All share and per share amounts
disclosed in this document have been restated to reflect this stock split. The total
number of shares outstanding at the stock split pay date was 12,385,916.

9.    
          EXCESS OF COST OVER NET TANGIBLE ASSETS ACQUIRED AND CUSTOMER LISTS

In June 2001, the FASB issued SFAS
No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other
Intangible Assets. Under the new rules, goodwill and indefinite lived intangible
assets are no longer amortized but are reviewed annually for impairment, or more
frequently if impairment indicators arise. The review process entails assessing the fair
value of the net assets underlying the Companys acquisition related goodwill on a
business-by- business basis. If the fair value is deemed less than the related carrying
value, the Company is required to reduce the amount of the goodwill. Separable intangible
assets that are not deemed to have an indefinite life continue to be amortized over their
useful lives.

The Company has applied the new
accounting rules to goodwill and intangible assets, all of which were acquired prior to
July 1, 2001. As of February 28, 2003, the financial statements included
acquisition-related goodwill of $27.2 million, net of previous amortization of $7.1
million. Goodwill, net of amortization, totaled $17.8 million, $2.6 million, $0.9 million
and $5.9 million in the U.S., Germany, Italy and Canada, respectively. The Company tested
goodwill for impairment as of June 1, 2002, as required by SFAS No. 142, utilizing a
combination of valuation techniques including the expected present value of future cash
flows and a market multiple approach. This analysis did not result in impairment at June
1, 2002. The Company no longer amortizes acquisition-related goodwill. The table below
shows the periods ended February 28, 2003 and 2002 on a comparative basis given the
adoption of the amortization provisions of SFAS 142.

|Three Months Ended                        | Nine Months Ended
|----------------------------------------- | -----------------
|
|
|                                          |                  
|Net income as reported                    |                  
|Add:  Goodwill amortization, net of taxes |                  
|                                          |                  
|Net income as adjusted for SFAS No. 142   |                  
|Net income per basic share:               |                  
|As reported                               |                  
|As adjusted                               |                  
|Net income per diluted share:             |                  
|As reported                               |                  
|As adjusted                               |                  

---

Excess of Cost Over Net Tangible
Assets Acquired had included a $1.7 million customer list that is now reported separately
on the balance sheet. Accumulated amortization of the customer list as of February 28,
2003 and May 31, 2002, was $0.37 million and $0.30 million, respectively.

The customer list is being amortized
over a useful life of 20 years. The estimated amortization expense relating to the
customer list for each of the next five fiscal years is as follows:

| | 2003       |  | $     85,000 | 
| | ---------- |  | ------------ | 
| | 2004       |  | 85,000       | 
| | 2005       |  | 85,000       | 
| | 2006       |  | 85,000       | 
| | 2007       |  | 85,000       | 
| | Thereafter |  | 970,000      | 
| |           
| |            |  | $1,395,000   | 
| |           

10.    
          LOAN AMENDMENT

On July 18, 2002, the Company amended
its loan agreement with its primary lender. The amendment extended the term of the lines
of credit from February 28, 2003 to December 1, 2005. Borrowings under the senior credit
facility will be priced subject to a pricing grid that varies based upon the
Companys Funded Debt to EBITDA, as defined in the senior credit facility. The
interest rate on the effective date of the amendment was LIBOR plus 200 basis points on
the revolving lines of credit and Term Loan A and LIBOR plus 250 basis points on Term Loan
B. Pricing under the amendment did not change from the original loan agreement dated
February 2001. At February 28, 2003 there was approximately $18.7 million outstanding
under the revolvers and Term Loan A and approximately $6.0 million outstanding under Term
Loan B.

---

Certain statements that Immucor
may make from time to time, including statements contained in this report, constitute
forward-looking statements under the federal securities laws. Forward-looking
statements may be identified by words such as plans, expects,
believes, anticipates, estimates,
projects, will and other words of similar meaning used in
conjunction with, among other things, discussions of future operations, financial
performance, product development and new product launches, market position, revenues and
expenditures. Factors that could cause actual results to differ materially from those
expressed in any forward-looking statement made by, or on behalf of, Immucor include the
following, some of which are described in greater detail below: the decision of customers
to defer capital spending, increased competition in the sale of instruments and reagents,
changes in interest rates, the timing and results of clinical trials of the Galileo
instrument or other products, and general economic conditions. In addition, the
strengthening of the dollar versus the Euro would adversely impact reported European
results. Investors are cautioned not to place undue reliance on any forward-looking
statements. Immucor cautions that historical results should not be relied upon as
indications of future performance. Immucor assumes no obligation to update any
forward-looking statements.

# Critical Accounting
Policies

General

We have identified the policies below
as critical to our business operations and the understanding of our results of operations.
The impact and any associated risks related to these policies on our business operations
is discussed throughout Managements Discussion and Analysis of Financial Condition
and Results of Operations where such policies affect our reported and expected financial
results. For a detailed discussion on the application of these and other accounting
policies, see Note 1, Note 6 and Note 9 to the Consolidated Financial Statements of this
Quarterly Report on Form 10-Q. Note that our preparation of this Form 10-Q requires us to
make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of our financial
statements, and the reported amounts of revenue and expenses during the reporting period.
Actual results could differ from those estimates, and certain assumptions could prove to
be incorrect.

Revenue Recognition

The Company recognizes revenue in
accordance with SEC Staff Accounting Bulletin No. 101, Revenue Recognition in Financial
Statements(SAB 101), as amended by SAB 101A and 101B. SAB 101 requires
that four basic criteria must be met before revenue can be recognized: (1) persuasive
evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the
fee is fixed and determinable; and (4) collectibility is reasonably assured. Should
changes in conditions cause management to determine these criteria are not met for certain
future transactions, revenue recognized for any reporting period could be adversely
affected. Revenue from the sale of the Companys reagents is recognized upon shipment
since both title and risk of loss transfers to the customer upon shipment. Revenue from
the sale of the Companys medical instruments is recognized upon shipment and
completion of contractual obligations relating to training and/or installation based on
terms of the related agreements. Revenue from rentals of the Companys medical
instruments is recognized over the life of the rental agreement.

Allowance for Doubtful
Accounts

Immucor maintains allowances for
doubtful accounts for estimated losses resulting from the inability of its customers to
make required payments. The allowance is approximately 5.9% of the accounts receivable
balance. The Company continually monitors the collectibility of its customer accounts and
when indications arise that amounts are not likely to be collected, the amount is charged
to the allowance for doubtful accounts. If the financial condition of Immucors
customers were to deteriorate, resulting in an impairment of their ability to make
payments, additional allowances could be required.

---

Inventory

Inventories are stated at the lower
of first-in, first-out cost or market. Cost includes material, labor and manufacturing
overhead. The Company uses a standard cost system that applies labor and manufacturing
overhead factors to inventory based on budgeted production levels, staffing levels and
costs of operation. Actual costs and production levels may vary from the standard and will
be charged to the consolidated statement of operations as a component of cost of sales.

Goodwill and Other
Long-lived Assets

In assessing the recoverability of
the Companys goodwill and other long-lived assets the Company must make assumptions
regarding estimated future cash flows and other factors to determine the fair value of the
respective assets. If these estimates or their related assumptions change in the future,
the Company may be required to record impairment charges for these assets not previously
recorded. On June 1, 2002 the Company adopted Statement of Financial Accounting Standards
(SFAS) No. 142, Goodwill and Other Intangible Assets, and is required
to analyze its goodwill and intangible assets for impairment on an annual basis or more
frequently if impairment indicators arise. In October 2001, the FASB issued SFAS No. 144,
Accounting for the Impairment or Disposal of Long-Lived Assets. The Statement
supercedes SFAS No. 121, Accounting for the Impairment of Long-Lived Assets and for
Long-Lived Assets to be Disposed of,however it retains the fundamental provisions of
that statement related to the recognition and measurement of the impairment of long-lived
assets to be held and used. The Company adopted SFAS No. 144 effective June 1,
2002 without impact on its financial position or results of operations.

Income Taxes

Our income tax policy records the
estimated future tax effects of temporary differences between the tax bases of assets and
liabilities and amounts reported in the accompanying consolidated balance sheets, as well
as operating loss and tax credit carry-forwards. We follow very specific and detailed
guidelines regarding the recoverability of any tax assets recorded on the balance sheet
and provide any allowances as required. The Company believes that the value of the
Companys deferred tax assets assumes that the Company will be able to generate
sufficient future taxable income in certain tax jurisdictions, based on estimates and
assumptions. If these estimates and related assumptions change in the future, the Company
may be required to record additional valuation allowances against its deferred tax assets
resulting in additional income tax expense in the Companys consolidated statements
of operations. In assessing the realizability of deferred tax assets, management considers
whether it is more likely than not that some portion or all of the deferred tax assets
will not be realized. Management considers the scheduled reversal of deferred tax
liabilities, projected future taxable income, carry back opportunities, and tax planning
strategies in making this assessment. Management evaluates the realizability of the
deferred tax assets and assesses the need for additional valuation allowances quarterly.

Stock-based Employee
Compensation

The Company grants stock options for
a fixed number of shares to employees with an exercise price equal to the fair value of
the shares at the date of the grant. The Company accounts for stock option grants in
accordance with APB Opinion No. 25, Accounting for Stock Issued to Employees, and
accordingly does not recognize compensation expense for the stock option grants. As
currently required by SFAS No. 123, Accounting for Stock-Based Compensation, in the
annual report on Form 10K, the Company presents supplemental information disclosing pro
forma net income and net income per common share as if the Company had recognized
compensation expense on stock options granted subsequent to May 31, 1995 under the fair
value method of that statement. In December 2002, the FASB issued SFAS No. 148,
Accounting for Stock-Based Compensation  Transition and Disclosure  an
amendment of FASB Statement No. 123.This Statement provides alternative methods of
transition for a voluntary change to the fair value based method of accounting for
stock-based employee compensation. In addition, this Statement amends the disclosure
requirements of Statement 123 to require prominent disclosures in both annual and interim
financial statements about the method of accounting for stock-based employee compensation
and the effect of the method used on reported results. The interim disclosure requirements
are effective for financial reports containing condensed consolidated financial statements
for interim periods beginning after December 15, 2002. Consequently, the Company will
adopt the interim disclosure requirements with the period ended May 31, 2003.

---

# Financial Condition,
Liquidity and Capital Resources

As of February 28, 2003 the
Companys cash and cash equivalents balance totaled $5.3 million, a decrease of $0.5
million over the balance as of November 30, 2002 and $1.4 million over the balance as of
February 28, 2002. Net working capital as of February 28, 2003 increased to $37.6 million,
an improvement of $2.4 million, from $35.2 million as of November 30, 2002 and an
improvement of $26.5 million from $11.1 million as of February 28, 2002. The price
increases implemented in fiscal 2002 have significantly strengthened the Companys
financial position. As a consequence of the improved results, the Company experienced a
rise in the value of its stock and, as a result, option holders have exercised a large
number of options bringing an additional influx of cash. The effect of exchange rate
changes increased cash at February 28, 2003 by approximately $1.9 million from May 31,
2002.

Net cash provided by operating
activities totaled approximately $7.4 million and $9.4 million for the nine-month periods
ended February 28, 2003 and February 28, 2002, respectively. Positive results from
operations had a favorable effect on net cash from operations. During the nine-month
period ended February 28, 2003, the Company improved net income by $4.2 million over the
nine-month period ended February 28, 2002. Revenues for the nine-month period ended
February 28, 2003 increased $11.3 million over the nine-month period ended February 28,
2002, primarily as a result of reagent price increases in the United States and increased
instrument sales. Sales of the Galileo instrument to distributors in Europe were much
stronger than expected during the nine-month period ending February 28, 2003. Gross
margin, as a percentage of sales, was 57.5% and 54.4% for the nine-month periods ended
February 28, 2003 and February 28, 2002, respectively. The strong sales for the nine-month
period ended February 28, 2003 of the Galileo instrument through the third party
distributor network in Europe, whose sales margins are generally lower than reagent sales
margins, negatively impacted total gross margin by approximately 1% and 2%, respectively.

During the nine months ended February
28, 2003, $3.5 million of cash was used in investing activities for capital expenditures
which included approximately $0.6 million for expansion of the Companys computer
network capabilities, $0.9 million to refurbish the German facility and update its
computer network, $0.7 million for Galileo and other reagent rental instruments installed
in Europe and $1.3 million for manufacturing and quality system improvements at its
Norcross and Houston facilities. Planned capital expenditures for fiscal 2003 total
approximately $4.1 million, and include approximately $0.3 million for U.S. clinical trial
Galileo instruments, approximately $1.3 million for Galileo reagent rental instruments
installed in Europe, $1.3 million for manufacturing and quality system improvements at its
domestic manufacturing facilities and $1.2 million for expansion of its computer network
capabilities.

Net cash flow used in financing
activities for the nine-month period ended February 28, 2003 approximated $4.5 million.
During the quarter, the Company paid off the German line-of-credit with the primary lender
in the amount of $2.8 million. Operating cash flows provided $1.8 million of the funds and
$1.0 million was borrowed against the U.S. line-of-credit. During the nine-month period
the Company received $7.3 million in cash from the exercise of stock options. These
options were granted in prior fiscal years and provided for exercise prices equal to the
market value of the Companys stock on the date granted. The Company experienced a
rise in the value of its stock during the recently completed fiscal year and as a result
option holders have exercised a large number of options. For the nine months, the Company
paid $11.9 million of long-term debt net of borrowings, borrowings under lines-of-credit,
debt issue costs and capital lease obligations.

Accounts receivable increased by
approximately $4.0 million from May 31, 2002 mainly due to slower collections in Europe,
primarily in Italy. The Company has entered into a contract to factor certain Italian
accounts receivable and is evaluating the possibility of factoring additional Italian
accounts receivable. The exchange rate effect of the Euro versus the dollar increased
accounts receivable by approximately $2.4 million. Inventory increased by approximately
$3.0 million for the nine-month period with the purchase of Galileo instruments for
product launch, increased finished product stock levels to minimize customer backorders,



and increased inventory carrying value as additional quality system improvements are
completed. The exchange rate effect of the Euro versus the dollar increased inventory by
approximately $0.4 million. In August 2002, Immucor placed an order, amounting to $3.3
million, for 50 additional ABS2000 instruments. Five of the ABS2000 instruments were
received during this quarter. Income tax refund receivable decreased due to the refund of
tax overpayments in the German subsidiary. Prepaid and other assets increased due
primarily to prepayments on the order for additional ABS2000 instruments. The reduction in
other long-term assets includes the decrease in deferred instrument costs for instruments,
previously shipped but not recognized as revenue, whose contracts have now been completed.
Deferred licensing costs and customer list declined due to normal amortization and excess
of cost over net tangible assets acquired increased due to the exchange rate effect of the
Euro on the Companys European subsidiaries.

Accounts payable declined $1.0
million during the period due to increased availability of funds from the exercise of
stock options. The current income tax liability decreased due to estimated tax payments
for 2003 and extension tax payments for 2002 made during the period and the tax benefit of
$3.0 million related to the stock option exercises. Accrued salaries and wages and other
accrued liabilities decreased by $0.4 million as the May 31, 2002 year-end accrual for
executive, management and supervisory bonuses and other accruals for legal, audit and
royalties fees were paid during the current period. Other long-term liabilities increased
by $0.4 million primarily due to the change in value of the interest rate swap agreement
and reclassification from other accrued liabilities of deferred revenue on instrument
contracts for which the cash has been received and for which revenue is being recognized
monthly due to contractual restrictions.

Common stock and additional paid-in
capital increased by an aggregate of $9.7 million primarily due to the exercise of stock
options, described above, and the related tax benefit for disqualified dispositions of
common stock. Also, common stock increased and retained earnings decreased by $0.4 million
due to the effect of the three-for-two stock split on September 13, 2002. Retained
earnings and (comprehensive loss) improved by $12.6 million due to the earnings for the
year and favorable changes in the net foreign exchange translation. The financial
statements of foreign subsidiaries have been translated into U.S. dollars in accordance
with FASB Statement No. 52, Foreign Currency Translation. All balance sheet
accounts have been translated using the exchange rates in effect at the balance sheet
dates. Income statement amounts have been translated using the average exchange rates for
each period. The gains and losses resulting from the changes in exchange rates from year
to year have been reported separately as a component of comprehensive income. The effect
of foreign currency transaction gains and losses has been recorded in the accompanying
statements of operations.

In July 2002, the Company and its
primary lender amended their loan agreement to extend the term of the existing revolving
lines of credit from February 28, 2003 to December 1, 2005. Borrowings under the senior
credit facility were re-priced according to a price that varies based upon the
Companys ratio of Funded Debt to EBITDA, as defined in the senior credit facility.
The interest rate on the effective date of the amendment was LIBOR plus a spread of 200
basis points on the revolving lines of credit and Term Loan A and LIBOR plus a spread of
250 basis points on Term Loan B. The balance of the senior credit facility as of February
28, 2003 was $24.7 million. To optimize their cashflow, the Italian subsidiary has
utilized various capital lease obligations to finance approximately $0.8 million of
instruments installed at customer sites under reagent agreements.

Management is focused on reducing the
leverage on the Companys balance sheet and does not anticipate that there will be a
need for additional borrowings. Management expects that cash and cash equivalents and
internally generated funds will be sufficient to support operations, scheduled debt
repayments and planned capital expenditures.

# Results of Operations

For the quarter ended February 28,
2003 revenues totaled $25.1 million, a $4.0 million, or 19.0% increase over the quarter
ended February 28, 2002. For the nine-month period ended February 28, 2003 revenues
totaled $72.0 million, an $11.3 million, or 18.6% increase over the nine-month period
ended February 28, 2002. The increase in revenues occurred predominantly as a result of
renewals of group contracts and reagent price increases in the United States at
substantially higher prices and increased instrument sales. Income before income taxes



reached $5.3 million for the quarter and $15.4 million for the nine-month period ended
February 28, 2003 compared to income before income taxes of $3.3 million and $7.6 million
for the prior year quarter and nine-month period, respectively. Net income increased to
$3.7 million and $10.1 million for the three-month and nine-month periods ended February
28, 2003, respectively, versus net income of $2.5 million and $6.0 million for the
three-month and nine-month periods ended February 28, 2002, respectively. Diluted earnings
per share were $0.28 on 13.6 million weighted average shares outstanding for the quarter
ended February 28, 2003 compared with $0.21 on 11.7 million weighted average shares
outstanding, adjusted for the three-for-two stock split on September 13, 2002, for the
same period last year. Diluted earnings per share were $0.76 on 13.4 million weighted
average shares outstanding for the nine-month period ended February 28, 2003 compared with
$0.53 on 11.2 million weighted average shares outstanding, adjusted for the three-for-two
stock split on September 13, 2002, for the same period last year. The rise in the
Companys stock price over the past year has increased the dilutive effect of stock
options and warrants to approximately 0.9 million shares that are used to arrive at
diluted earnings per share.

Net sales

Sales of traditional reagent
products, i.e., products not utilizing the Companys patented Capture®
technology, increased $2.1 million, or 13.1%, from $16.0 million in the third quarter of
2002 to $18.1 million in the third quarter of 2003. Sales of Capture® products
increased approximately $0.8 million to $4.7 million, a 20% increase over the prior year
quarter. Sales of traditional reagent products increased $7.6 million, or 17%, from $45.6
million for the nine months ended February 28, 2002 to $53.2 million for the nine months
ended February 28, 2003. Sales of Capture® products increased approximately $1.3
million to $13.7 million, an 11% increase over the prior year-to-date period. The Company
believes growth in reagent revenue occurred as a result of price increases in North
America partially offset by declines in international sales, primarily in South American
countries that are experiencing financial difficulties, and the planned exit from the
distribution of certain low-margin third-party products. The Company will continue to
de-emphasize sales in South America until economic stability has been restored. Sales of
instruments increased $1.0 million, or 76.9%, from $1.3 million in the third quarter of
2002 to $2.3 million in the third quarter of 2003. Instrument sales for the first nine
months increased by approximately $2.3 million to $5.1 million, an increase of 79% over
the prior year period. Instrument revenue grew as a result of increased sales of the
Galileo instrument to distributors in Europe for both the
three-month period and nine-month periods ending February 28, 2003. Currently, the Company
is exclusively marketing this instrument to hospital transfusion laboratories and blood
donor centers for patient and donor blood typing and antibody screening and
identification. Based upon the Companys success to date, management believes that a
total of 50 Galileo instruments will be placed in Europe during this fiscal year. The
effect on revenues of the change in the Euro exchange rate was an increase of $0.9 million
and $2.3 million for the quarter and nine-month period ended February 28, 2003.

Cost of Sales

Cost of sales, as a percentage of
sales, totaled 42.6% versus 43.5% for the same quarter in the prior year and 42.5% versus
45.6% for the nine-month period ended February 28, 2003 and 2002, respectively. Cost of
sales increased approximately $1.5 million and $2.9 million for the quarter and nine-month
period ended February 28, 2003, respectively, as compared to the prior year period. The
increased sales volume of the Capture® products mentioned above were principally
generated through sales to the distributor network in Europe at margins to the Company
approximately 6% lower than achieved through direct sales in the U.S. Consequently, the
cost of sales on Capture® products increased from 28.7% for the nine-month period
ended February 28, 2002 to 30.2% for the nine-month period ended February 28, 2003, or
approximately $0.6 million. The effect on cost of sales of the change in the Euro exchange
rate accounted for approximately $0.5 million and $1.2 million of the quarter and year to
date increase, respectively. Galileo sales in Europe added an additional $0.2 million and
$1.1 million to cost of sales for the three-month and nine-month periods ended February 28,
2003, respectively, due to reduced margins related to the product line. The remainder of
the increase of cost of sales was the result of unfavorable manufacturing variances that
management is focused on improving over the coming months.

---

Operating expenses

When compared to the prior year,
research and development costs for the quarter and nine-month period ended February 28,
2003 increased 21.1% and declined 6.9%, respectively, from the prior year periods.
Increases in the current quarter are related to preparation for domestic field trials of
the Galileo instrument and are partially offset by a reduction of instrument development
initiatives for the launch of the Galileo in the European market for the year-to-date
period.

Selling and marketing expenses
increased $0.2 million for the quarter as compared to the same quarter in the prior year,
primarily as a result of the change in the Euro exchange rate. For the nine-month period
ended February 28, 2003, selling and marketing expenses increased $0.9 million as compared
to the prior year period, of which $0.6 million was a result of the change in the Euro
exchange rate. Travel and marketing expense increases associated with the sales effort in
Europe to market the Galileo accounted for the remainder of the increase for the year to
date.

Distribution expenses for the quarter
ended February 28, 2003 were relatively constant with the same quarter last year. Year to
date distribution expenses increased by $0.1 million compared to the prior year primarily
due to additional shipping expenses related to new customers and the implementation of a
new shipping package configuration designed to maintain acceptable environmental
temperatures and preserve product quality during shipment.

General and administrative expenses
for the period ended February 28, 2003 have risen approximately $0.4 million over the same
quarter in the prior year and $0.8 million over the same nine-month period in the prior
year. The change in the Euro exchange rate accounted for approximately $0.1 million and
$0.3 million of the increase in the quarter and year-to-date periods, respectively. The
remaining increases for the quarter and nine-month period are due to additional personnel
and expenditures to support domestic and international efforts to expand Company presence
and assure compliance with European Union quality regulations and accounting and SEC
regulatory mandates in the United States.

Amortization expense declined $0.3
million and $0.9 million for the quarter and nine-month period ended February 28, 2003 as
compared with the prior period due to the adoption of SFAS No.142, Goodwill and Other
Intangible Assets, which requires goodwill and indefinite lived intangible assets to
be reviewed annually for impairment, or more frequently if impairment factors arise,
instead of amortized. The Company tested goodwill for impairment as of June 1, 2002, as
required by SFAS No. 142, utilizing a combination of valuation techniques including the
expected present value of future cash flows and a market multiple approach. This analysis
did not result in an impairment at June 1, 2002. The Company expects amortization will be
approximately $1.2 million less in fiscal 2003 than in fiscal 2002.

Interest expense

When compared to the prior year,
interest expense decreased $0.3 million and $1.5 million in the quarter and nine-month
periods ended February 28, 2003. The decrease is primarily the result of reduced
borrowings on long-term debt and a more favorable interest rate that became effective in
May 2002 under the original loan agreement and continued with the July 2002 amendment to
the loan agreement. Also, lower amortization of debt issue costs due to the reset of
long-term debt maturity dates further reduced interest expense for the current periods.

Other income (expense)

The current quarter and nine-month
period ending February 28, 2003 amounts primarily reflect foreign currency transaction
gains that exceeded foreign currency transaction losses. Other income for the prior
nine-month period was favorably affected by the disgorgement of short-swing trading
profits by the Kairos Group in the amount of $0.4 million and by $1.0 million from the
settlement of the Becton, Dickinson arbitration.

---

Income taxes

Income tax expense increased $0.8
million and $3.7 million for the quarter and nine-month periods ended February 28, 2003,
as compared to the prior periods, due to higher income in the current periods and
utilization of net operating loss carry-forwards in the prior periods. During the fourth
quarter of fiscal 2001, the Company elected to record a valuation allowance in an amount
equal to the net deferred tax assets of the Company, amounting to $1.2 million due to
continued losses. Effectively, this non-cash allowance reflected the elimination of
domestic deferred taxes as a balance sheet asset and was subsequently used to reduce
domestic taxes in fiscal 2002 as the Company returned to profitability. The net operating
loss carry-forwards generated in fiscal 2001 also reduced the fiscal 2002 United States
tax provision and were fully utilized by the quarter ended February 28, 2002.

ITEM 3. Quantitative and
Qualitative Disclosures On Market Risk

There have been no material changes
regarding the Companys market risk position from the information provided in its
Annual Report on Form 10-K for the fiscal year ended May 31, 2002. The quantitative and
qualitative disclosures about market risk are discussed in Item 7A-Quantitative and
Qualitative Disclosures About Market Risk, contained in the Companys Annual Report
on Form 10-K.

ITEM 4. Controls and Procedures.

Within the 90 days prior to the date
of this report, the Company carried out an evaluation, under the supervision and with the
participation of the Companys management, including the Companys Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the design and
operation of the Companys disclosure controls and procedures pursuant to Exchange
Act Rule 13a-14. Based upon that evaluation, the Chief Executive Officer and Chief
Financial Officer concluded that the Companys disclosure controls and procedures are
effective. There were no significant changes in the Companys internal controls or in
other factors that could significantly affect these controls subsequent to the date of
their evaluation.

---

PART II

OTHER INFORMATION

(a)    
          The Company has filed the following exhibits with this report.

99.1       Certification of Chief Executive
Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated April 14, 2003.*

99.2       Certification of Chief Financial Officer
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated April 14, 2003.*

| |  | * |  | The certifications contained in these exhibits are not filed for purposes of
Section 18 of the Exchange Act [15 U.S.C. 78r], or otherwise subject to the liability of
that section. Such certifications will not be deemed to be incorporated by reference into
any filing under the Securities Act or the Exchange Act, except to the extent that the
Company specifically incorporates them by reference.
| |  | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(b)    
          The Company did not file any reports on Form 8-K during the three months ended
          February 28, 2003.

---

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.

IMMUCOR, INC.

(Registrant)

Date: April 14, 2003                                                                            By: /s/ Edward L. Gallup

| | Edward L. Gallup, President and Chief Executive Officer
                                                             (on behalf of Registrant and as Principal
Executive Officer)
| | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

/s/ Steven C.Ramsey

|Steven C. Ramsey, Senior Vice President - Finance
                                                                                                              (Principal Accounting Officer)
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

CERTIFICATIONS

I, Edward L. Gallup, certify that:

|1. |  | I have reviewed this quarterly report on Form 10-Q of Immucor, Inc.;
|-- |  | --------------------------------------------------------------------

|2. |  | Based on my knowledge, this quarterly report does not contain any untrue
               statement of a material fact or omit to state a material fact necessary to make
               the statements made, in light of the circumstances under which such statements
               were made, not misleading with respect to the period covered by this quarterly
               report;
|-- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|3. |  | Based on my knowledge, the financial statements, and other financial information
               included in this quarterly report, fairly present in all material respects the
               financial condition, results of operations and cash flows of the registrant as
               of, and for, the periods presented in this quarterly report;
|-- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|4. |  | The registrants other certifying officers and I are responsible for
               establishing and maintaining disclosure controls and procedures (as defined in
               Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|a) |  | designed such disclosure controls and procedures to ensure that material
                    information relating to the registrant, including its consolidated subsidiaries,
                    is made known to us by others within those entities, particularly during the
                    period in which this quarterly report is being prepared;
|-- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|b) |  | evaluated the effectiveness of the registrants disclosure controls and
                    procedures as of a date within 90 days prior to the filing date of this
                    quarterly report (the Evaluation Date); and
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|c) |  | presented in this quarterly report our conclusions about the effectiveness of
                    the disclosure controls and procedures based on our evaluation as of the
                    Evaluation Date;
|-- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|5. |  | The registrants other certifying officers and I have disclosed, based on
               our most recent evaluation, to the registrants auditors and the audit
               committee of registrants board of directors (or persons performing the
               equivalent function):
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|a) |  | all significant deficiencies in the design or operation of internal controls
                    which could adversely affect the registrants ability to record, process,
                    summarize and report financial data and have identified for the
                    registrants auditors any material weaknesses in internal controls; and
|-- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|b) |  | any fraud, whether or not material, that involves management or other employees
                    who have a significant role in the registrants internal controls; and
|-- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|6. |  | The registrants other certifying officers and I have indicated in this
               quarterly report whether or not there were significant changes in internal
               controls or in other factors that could significantly affect internal controls
               subsequent to the date of our most recent evaluation, including any corrective
               actions with regard to significant deficiencies and material weaknesses.
|-- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date April 14, 2003

/s/ Edward L. GallupEdward L. Gallup,
President (Principal Executive Officer)

---

I, Steven C. Ramsey, certify that:

|1. |  | I have reviewed this quarterly report on Form 10-Q of Immucor, Inc.;
|-- |  | --------------------------------------------------------------------

|2. |  | Based on my knowledge, this quarterly report does not contain any untrue
               statement of a material fact or omit to state a material fact necessary to make
               the statements made, in light of the circumstances under which such statements
               were made, not misleading with respect to the period covered by this quarterly
               report;
|-- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|3. |  | Based on my knowledge, the financial statements, and other financial information
               included in this quarterly report, fairly present in all material respects the
               financial condition, results of operations and cash flows of the registrant as
               of, and for, the periods presented in this quarterly report;
|-- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|4. |  | The registrants other certifying officers and I are responsible for
               establishing and maintaining disclosure controls and procedures (as defined in
               Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|a) |  | designed such disclosure controls and procedures to ensure that material
                    information relating to the registrant, including its consolidated subsidiaries,
                    is made known to us by others within those entities, particularly during the
                    period in which this quarterly report is being prepared;
|-- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|b) |  | evaluated the effectiveness of the registrants disclosure controls and
                    procedures as of a date within 90 days prior to the filing date of this
                    quarterly report (the Evaluation Date); and
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|c) |  | presented in this quarterly report our conclusions about the effectiveness of
                    the disclosure controls and procedures based on our evaluation as of the
                    Evaluation Date;
|-- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|5. |  | The registrants other certifying officers and I have disclosed, based on
               our most recent evaluation, to the registrants auditors and the audit
               committee of registrants board of directors (or persons performing the
               equivalent function):
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|a) |  | all significant deficiencies in the design or operation of internal controls
                    which could adversely affect the registrants ability to record, process,
                    summarize and report financial data and have identified for the
                    registrants auditors any material weaknesses in internal controls; and
|-- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|b) |  | any fraud, whether or not material, that involves management or other employees
                    who have a significant role in the registrants internal controls; and
|-- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|6. |  | The registrants other certifying officers and I have indicated in this
               quarterly report whether or not there were significant changes in internal
               controls or in other factors that could significantly affect internal controls
               subsequent to the date of our most recent evaluation, including any corrective
               actions with regard to significant deficiencies and material weaknesses.
|-- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: April 14, 2003

/s/ Steven C. RamseySteven C. Ramsey,
Senior Vice President  Finance (Principal Financial Officer)

---

# EXHIBIT INDEX

# Number Description

99.1      Certification of Chief Executive
Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated April 14, 2003.*

99.2      Certification of Chief Financial Officer
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated April 14, 2003.*

| |  | * |  | The certifications contained in these exhibits are not filed for purposes of
Section 18 of the Exchange Act [15 U.S.C. 78r], or otherwise subject to the liability of
that section. Such certifications will not be deemed to be incorporated by reference into
any filing under the Securities Act or the Exchange Act, except to the extent that the
Company specifically incorporates them by reference.
| |  | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------